Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Splenic Marginal Zone Lymphoma

The present study investigated the potential value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography metabolic features in estimating progression-free survival (PFS) and overall survival (OS) in patients affected by splenic marginal zone lymphoma. The estimated 2-year PFS and OS rates were 78% and 90%, whereas 5-year PFS and OS rates were 63% and 82%. Only lesion to liver maximum standardized uptake value ratio and lesion to blood-pool maximum standardized uptake value ratio were independent prognostic factors for PFS. By contrast, for OS, no positron emission tomography/computed tomography features were correlated with outcome.